Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic disorders worldwide. Although its true prevalence is difficult to determine ...
Hematology-oncology-trained physicians who treat sickle cell disease reported higher rates of burnout (60%) than their counterparts who do not provide sickle cell care (43%) despite no differences in ...
ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.
CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...
CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...
Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...
Advocates stress that while gene therapy is causing a buzz in wealthy countries, African governments must prioritise prevention, screening and accessible treatment NEWS ANALYSIS | JOHN MUSENZE | As ...
CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...
Morning Overview on MSN
Gene editing advances raise real prospects for future DNA upgrades
The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...
As Uganda rolls out mandatory nationwide screening of newborns for sickle cell disease this month, a gene therapy celebrated in the United States and Europe remains financially out of reach for most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results